Vertex Energy (VTNR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...
Vertex Pharmaceuticals Incorporated data readout from a phase 3 program, using VX-548 for the treatment of patients with acute pain, could be released by the 1st half of 2024. Proof of concept, using ...
Vertex Pharmaceuticals (NASDAQ: VRTX) is trading near a record high after climbing about 20% so far this year, and delivering a triple-digit gain over three years. So, you may be a bit hesitant about ...
Hosted on MSN
Here’s Why Vertex Pharmaceuticals (VRTX) is on Loomis Sayles Growth Fund’s Detractors List
Loomis Sayles, an investment management company, released its “Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned ...
Days before three scientists at Boston-based Vertex Pharmaceuticals will share a $3 million prize for revolutionizing the treatment of cystic fibrosis, the award — sometimes called the Oscars of ...
Vertex Pharmaceuticals and CRISPR Therapeutics just met with regulators at the Food and Drug Administration. The discussion was about the safety of their gene therapy candidate called exa-cel. There ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at least as effective and costs only 50 cents a pill? They will if the generic ...
Shares of Vertex Pharmaceuticals soared in 2022 while the major stock market indexes tumbled. Vertex Pharmaceuticals markets the only drugs approved to treat cystic fibrosis, a progressive inherited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback